Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma
Last Updated: Friday, July 17, 2026
Ten European experts share their clinical experience regarding optimal bridging therapy selection, efficacy, safety, and outcomes following CAR T-cell therapy. They focus on heavily pretreated patients and emerging options, including bispecific T-cell engagers.
Advertisement
News & Literature Highlights
